Global Ovarian Cancer Drug Market
Market Size in USD Billion
CAGR :
% 
 Forecast Period |
2023 –2023 |
 Market Size (Base Year) |
USD 2,678.00 Million |
 Market Size (Forecast Year) |
USD 7,423.00 Million |
 CAGR |
% |
| Major Markets Players |
|
Global Ovarian Cancer Drug Market, By Drug Class [Paclitaxel, Cisplatin, Adriamycin PFS (Doxorubicin Hydrochloride), Carboplatin, Cyclophosphamide, Platinol (Cisplatin), Paraplatin (Carboplatin), Doxorubicin Hydrochloride Liposome, Evacet (Doxorubicin Hydrochloride Liposome), Cytoxan (Cyclophosphamide), Paraplat (Carboplatin), Taxol (Paclitaxel), Neosar (Cyclophosphamide), Gemcitabine Hydrochloride, Platinol-AQ (Cisplatin), Topotecan Hydrochloride, Gemzar (Gemcitabine Hydrochloride), Hycamtin (Topotecan Hydrochloride), Doxorubicin Hydrochloride, LipoDox (Doxorubicin Hydrochloride Liposome), Dox-SL (Doxorubicin Hydrochloride Liposome), Clafen (Cyclophosphamide), Adriamycin RDF (Doxorubicin Hydrochloride), DOXIL (Doxorubicin Hydrochloride Liposome)] Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Industry Trends and Forecast to 2030.
Ovarian Cancer Drug Market Analysis and Size
Ovarian cancer is one of the most frequent type of cancer in women that chiefly affects the women who have gone through menopause. The general symptoms of ovarian cancer are bloating, pelvic or abdominal pain, fatigue, upset stomach, back pain and so forth. The prime reason of ovarian cancer is unknown however, the women are at high risk of getting it being over 50 years of age and who have a family history for the disease.
Data Bridge Market Research analyses that the ovarian cancer drug market which was USD 2,678.00 million in 2022, would reach up to USD 7,423.00 million by 2030, and is expected to undergo a CAGR of 14.3% during the forecast period. “Hospital Pharmacies” dominates the distribution channel segment of the ovarian cancer drug market owing to the larger patient pool opting for treatment for ovarian cancer in the hospital. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Ovarian Cancer Drug Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015-2020) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Drug Class [Paclitaxel, Cisplatin, Adriamycin PFS (Doxorubicin Hydrochloride), Carboplatin, Cyclophosphamide, Platinol (Cisplatin), Paraplatin (Carboplatin), Doxorubicin Hydrochloride Liposome, Evacet (Doxorubicin Hydrochloride Liposome), Cytoxan (Cyclophosphamide), Paraplat (Carboplatin), Taxol (Paclitaxel), Neosar (Cyclophosphamide), Gemcitabine Hydrochloride, Platinol-AQ (Cisplatin), Topotecan Hydrochloride, Gemzar (Gemcitabine Hydrochloride), Hycamtin (Topotecan Hydrochloride), Doxorubicin Hydrochloride, LipoDox (Doxorubicin Hydrochloride Liposome), Dox-SL (Doxorubicin Hydrochloride Liposome), Clafen (Cyclophosphamide), Adriamycin RDF (Doxorubicin Hydrochloride), DOXIL (Doxorubicin Hydrochloride Liposome)] Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Allergan Plc (Ireland), AstraZeneca (U.K.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), Merck KGaA (Germany), Syndax (U.S.), Clovis Oncology (U.S.), Boehringer Ingelheim International GmbH (Germany), GlaxoSmithKline plc (U.K.), Exelixis, Inc. (U.S.), KINTARA THERAPEUTIC, INC. (U.S.), Bristol-Myers Squibb Company (U.S.), Novartis AG (Switzerland), Johnson & Johnson Private Limited (U.S.), AbbVie Inc. (U.S.), Oasmia Pharmaceutical AB (Sweden), TESARO (U.S.), Amgen, Inc. (U.S.), Lilly (U.S.), Kazia Therapeutics (Australia), Genentech, Inc. (U.S.), Celgene (U.S.), NOVOGEN SAS (France), ImmunoGen, Inc. (U.S.), Spectrum Pharmaceuticals, Inc. (U.S.) |
|
Market Opportunities |
|
Market Definition
Ovarian cancer drugs are medications used to treat ovarian cancer. They include chemotherapy drugs such as carboplatin and paclitaxel, targeted therapies such as PARP inhibitors, immunotherapy drugs, and hormone therapy for hormone-sensitive cases. These drugs are chosen based on factors such as cancer stage, type, and patient health to effectively combat the disease.
Ovarian Cancer Drug Market Dynamics
Drivers
- Rising Incidence and Prevalence of Ovarian Cancer
Ovarian cancer is one of the most common gynecological cancers, and its prevalence continues to rise globally. The increasing number of diagnosed cases drives the demand for effective treatments
- Emerging Targeted Therapies
The introduction of targeted therapies, such as PARP inhibitors, angiogenesis inhibitors, and immune checkpoint inhibitors, has expanded the treatment arsenal for ovarian cancer, offering more options for patients
Opportunities
- Innovative Treatment Options
As the market grows, there is an increased incentive for pharmaceutical companies and researchers to develop innovative and more effective drugs for ovarian cancer treatment. This can lead to the discovery of new therapies that are more targeted and have fewer side effects
- Personalized Medicine
Advances in genomics and molecular profiling are leading to the development of personalized treatment approaches. Tailoring treatments to individual patients based on their genetic and molecular profiles can improve treatment outcomes and reduce adverse effects
Restraint/Challenge
- High Treatment Costs
Many ovarian cancer drugs and therapies are expensive, leading to financial burdens on patients and healthcare systems. Cost considerations can limit access to cutting-edge treatments
This ovarian cancer drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the ovarian cancer drug Market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth
Recent Development
- In May 2022, The Food and Drug Administration of the U.S. granted ImmunoGen approval. Mirvetuximab soravtansine monotherapy in patients with folate receptor alpha high platinum-resistant ovarian cancer who have previously been treated with 1-3 prior systemic treatments was submitted in the Biologics License Application by the organization
Global Ovarian Cancer Drug Market Scope
The ovarian cancer drug market is segmented on the basis of drug class and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Paclitaxel
- Cisplatin
- Adriamycin PFS (Doxorubicin Hydrochloride)
- Carboplatin
- Cyclophosphamide
- Platinol (Cisplatin)
- Paraplatin (Carboplatin)
- Doxorubicin Hydrochloride Liposome
- Evacet (Doxorubicin Hydrochloride Liposome)
- Cytoxan (Cyclophosphamide)
- Paraplat (Carboplatin)
- Taxol (Paclitaxel)
- Neosar (Cyclophosphamide)
- Gemcitabine Hydrochloride
- Platinol-AQ (Cisplatin)
- Topotecan Hydrochloride
- Gemzar (Gemcitabine Hydrochloride)
- Hycamtin (Topotecan Hydrochloride)
- Doxorubicin Hydrochloride
- LipoDox (Doxorubicin Hydrochloride Liposome)
- Dox-SL (Doxorubicin Hydrochloride Liposome)
- Clafen (Cyclophosphamide)
- Adriamycin RDF (Doxorubicin Hydrochloride)
- DOXIL (Doxorubicin Hydrochloride Liposome)
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Ovarian Cancer Drug Market Regional Analysis/Insights
The ovarian cancer drug market is analysed and market size insights and trends are provided by drug class and distribution channel as referenced above.
The countries covered in the ovarian cancer drug market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the ovarian cancer drug market because of the growing incidences of the ovarian cancer. Furthermore, the new product introductions, the amplified acceptance of novel therapeutics, and large target population will further boost the growth of the ovarian cancer drug market in the region during the forecast period.
Asia-Pacific is projected to observe significant amount of growth in the ovarian cancer drug market because of the increasing prevalence of the ovarian cancer and the advantageous healthcare reforms. Moreover, the low expense base, the absence of controlling and cultural inhibitions are further expected to propel the growth of the ovarian cancer drug market in the region in the coming years.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The ovarian cancer drug market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for ovarian cancer drug market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Ovarian cancer drug Market. The data is available for historic period 2010 to 2020.
Competitive Landscape and Ovarian Cancer Drug Market Share Analysis
The ovarian cancer drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company’s focus related to ovarian cancer drug market.
Some of the major players operating in the ovarian cancer drug market are:
- Allergan Plc (Ireland)
- AstraZeneca (U.K.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Pfizer Inc. (U.S.)
- Merck KGaA (Germany)
- Syndax (U.S.)
- Clovis Oncology (U.S.)
- Boehringer Ingelheim International GmbH (Germany)
- GlaxoSmithKline plc (U.K.)
- Exelixis, Inc. (U.S.)
- KINTARA THERAPEUTIC, INC. (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Novartis AG (Switzerland)
- Johnson & Johnson Private Limited (U.S.)
- AbbVie Inc. (U.S.)
- Oasmia Pharmaceutical AB (Sweden)
- TESARO (U.S.)
- Amgen, Inc. (U.S.)
- Lilly (U.S.)
- Kazia Therapeutics (Australia)
- Genentech, Inc. (U.S.)
- Celgene (U.S.)
- NOVOGEN SAS (France)
- ImmunoGen, Inc. (U.S.)
- Spectrum Pharmaceuticals, Inc. (U.S.)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
